Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135016 | 0.91 | CIT (0.81) | CIT | |
| SCHEMBL30135147 | 0.87 | CIT (0.82) | CIT | |
| SCHEMBL30135099 | 0.86 | CIT (1.00) | CIT | |
| SCHEMBL30135155 | 0.84 | CIT (0.85) | CIT | |
| SCHEMBL30135046 | 0.84 | CIT (1.00) | CIT | |
| SCHEMBL30135126 | 0.84 | CIT (1.00) | CIT | |
| SCHEMBL30134879 | 0.83 | CIT (1.00) | CIT | |
| SCHEMBL30134861 | 0.83 | CIT (1.00) | CIT | |
| SCHEMBL30134930 | 0.81 | CIT (1.00) | CIT | |
| SCHEMBL30134870 | 0.81 | CIT (1.00) | CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | CIT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.